<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02813135</url>
  </required_header>
  <id_info>
    <org_study_id>2016-000133-40</org_study_id>
    <secondary_id>2016/2396</secondary_id>
    <nct_id>NCT02813135</nct_id>
  </id_info>
  <brief_title>European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors</brief_title>
  <acronym>ESMART</acronym>
  <official_title>European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The first molecular profiling protocols have been launched in Europe (MOSCATO-01 (Geoerger
      2014), MAPPYACTS, INFORM, iTHER, SM-PAEDS, etc.) determining multiple actionable alterations
      in pediatric recurrent cancers. Increasingly, stratified approaches are being implemented to
      enrich clinical trials of molecularly targeted agents and possibly improve outcomes in
      specific populations i.e. a molecularly enriched/predictive biomarker-driven approach. The
      diversity and heterogeneity of the detected molecular alterations and the low number of
      pediatric patients mandate an adapted, innovative trial design for the attributed treatment
      options in order to satisfy the current unmet medical need.

      This basket trial is designed to cover the targeting of several survival pathways in
      oncogenesis that are currently not adequately employed for pediatric patients in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response</measure>
    <time_frame>Objective tumor response will be measured according to RECIST 1.1 , RANO for HGG and INRC for NB after 56 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time to progression will be measured according to RECIST 1.1 , RANO for HGG and INRC for NB after after 56 days</time_frame>
  </primary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Anticipated">285</enrollment>
  <condition>Children, Adolescents and Young Adults With Refractory or Recurrent Malignancies</condition>
  <arm_group>
    <arm_group_label>ARM A. Ribociclib + Topotecan and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM B. Ribociclib + Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM C. AZD1775 + Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM D. Olaparib + Irinotecan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM E. AZD2014 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ARM F. AZD2014 + Topotecan and Temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G. Nivolumab + Cyclophosphamide +/- RT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribociclib</intervention_name>
    <arm_group_label>ARM A. Ribociclib + Topotecan and Temozolomide</arm_group_label>
    <arm_group_label>ARM B. Ribociclib + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <arm_group_label>ARM A. Ribociclib + Topotecan and Temozolomide</arm_group_label>
    <arm_group_label>ARM F. AZD2014 + Topotecan and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <arm_group_label>ARM A. Ribociclib + Topotecan and Temozolomide</arm_group_label>
    <arm_group_label>ARM F. AZD2014 + Topotecan and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <arm_group_label>ARM B. Ribociclib + Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD1775</intervention_name>
    <arm_group_label>ARM C. AZD1775 + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>ARM C. AZD1775 + Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olaparib</intervention_name>
    <arm_group_label>ARM D. Olaparib + Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <arm_group_label>ARM D. Olaparib + Irinotecan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2014</intervention_name>
    <arm_group_label>ARM E. AZD2014 single agent</arm_group_label>
    <arm_group_label>ARM F. AZD2014 + Topotecan and Temozolomide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <arm_group_label>Arm G. Nivolumab + Cyclophosphamide +/- RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <arm_group_label>Arm G. Nivolumab + Cyclophosphamide +/- RT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy</intervention_name>
    <arm_group_label>Arm G. Nivolumab + Cyclophosphamide +/- RT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must be diagnosed with a malignancy that has progressed despite standard
             therapy, or for which no effective standard therapy exists.

          2. Age &lt; 18 years at inclusion; patients 18 years and older may be included after
             discussion with the sponsor if they have a pediatric recurrent/refractory malignancy.

          3. Patient must have had advanced molecular profiling of their recurrent or refractory
             tumor i.e. at the time of disease progression/relapse; exceptionally patients with
             advanced molecular profiling at diagnosis may be allowed.

          4. Evaluable or measurable disease as defined by standard imaging criteria for the
             patient's tumor type (RECIST v1.1, RANO criteria for patients with HGG, INRC criteria
             for patients with NB, Leukemia criteria, etc.).

          5. Patients with relapsed or refractory leukemia are eligible for this study.

          6. Performance status: Karnofsky performance status (for patients &gt;12 years of age) or
             Lansky Play score (for patients ≤12 years of age) ≥ 70%. Patients who are unable to
             walk because of paralysis or stable neurological disability, but who are up in a
             wheelchair, will be considered ambulatory for the purpose of assessing the performance
             score.

          7. Life expectancy ≥ 3 months

          8. Adequate organ function:

             Hematologic criteria (Leukemia patients are excluded from hematological criteria):

               -  Peripheral absolute neutrophil count (ANC) ≥ 1000/μL(unsupported)

               -  Platelet count ≥ 100,000/μL (unsupported)

               -  Hemoglobin ≥ 8.0 g/dL (transfusion is allowed)

             Cardiac function:

               -  Shortening fraction (SF) &gt;29% (&gt;35% for children &lt; 3 years) and left ventricular
                  ejection fraction (LVEF) ≥50% at baseline, as determined by echocardiography
                  (mandatory only for patients who have received cardiotoxic therapy).

               -  Absence of QTc prolongation (QTc &gt; 450 msec on baseline ECG, using the Fridericia
                  correction [QTcF formula]) or other clinically significant ventricular or atrial
                  arrhythmia.

             Renal and hepatic function:

               -  Serum creatinine ≤ 1.5 x upper limit of normal (ULN) for age

               -  Total bilirubin ≤ 1.5 x ULN

               -  Alanine aminotransferase (ALT)/serum glutamic pyruvic transaminase (SGPT) ≤ 3 x
                  ULN; aspartate aminotransferase (AST)/serum glutamic oxaloacetic
                  transaminase/SGOT ≤ 3 x ULN except in patients with documented tumor involvement
                  of the liver who must have AST/SGOT and ALT/SGPT ≤ 5 x ULN.

          9. Able to comply with scheduled follow-up and with management of toxicity.

         10. Females of childbearing potential must have a negative serum or urine pregnancy test
             within 7 days prior to initiation of treatment. Sexually active patients must agree to
             use acceptable and appropriate contraception while on study drug and for 6 months
             after stopping the study drug. Acceptable contraception are defined in CTFG Guidelines
             &quot;Recommendations related to contraception and pregnancy testing in clinical trials&quot;

         11. For all oral medications patients must be able to comfortably swallow capsules (except
             for those for which an oral solution is available); nasogastric or gastrostomy feeding
             tube administration is allowed only if indicated.

         12. Written informed consent from parents/legal representative, patient, and
             age-appropriate assent before any study-specific screening procedures are conducted
             according to local, regional or national guidelines.

         13. Patient affiliated to a social security regimen or beneficiary of the same according
             to local requirements.

        Exclusion Criteria:

          1. Patients with symptomatic central nervous system (CNS) metastases who are
             neurologically unstable or require increasing doses of corticosteroids or local
             CNS-directed therapy to control their CNS disease. Patients on stable doses of
             corticosteroids for at least 7 days prior to receiving study drug may be included.

          2. Impairment of gastrointestinal (GI) function or GI disease that may significantly
             alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea,
             vomiting, diarrhea, or malabsorption syndrome).

          3. Clinically significant, uncontrolled heart disease (including history of any cardiac
             arrhythmias, e.g., ventricular, supraventricular, nodal arrhythmias, or conduction
             abnormality within 12 months of screening)

          4. Active viral hepatitis or known human immunodeficiency virus (HIV) infection or any
             other uncontrolled infection.

          5. Presence of any ≥ CTCAE grade 2 treatment-related toxicity with the exception of
             alopecia, ototoxicity or peripheral neuropathy.

          6. Systemic anticancer therapy within 21 days of the first study dose or 5 times its
             half-life, whichever is less.

          7. Previous myeloablative therapy with autologous hematopoietic stem cell rescue within 8
             weeks of the first study drug dose

          8. Allogeneic stem cell transplant within 3 months prior to the first study drug dose.
             Patients receiving any agent to treat or prevent graft-versus host disease (GVHD) post
             bone marrow transplant are not eligible for this trial.

          9. Radiotherapy (non-palliative) within 21 days prior to the first dose of drug (or
             within 6 weeks for therapeutic doses of MIBG or craniospinal irradiation).

         10. Major surgery within 21 days of the first dose. Gastrostomy, ventriculo-peritoneal
             shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access
             devices are not considered major surgery, but for these procedures, a 48 hour interval
             must be maintained before the first dose of the investigational drug is administered.

         11. Currently taking medications with a known risk of prolonging the QT interval or
             inducing Torsades de Pointes (Refer to Appendix 8).

         12. Currently taking medications that are mainly metabolized by CYP3A4/5, CYP2C8, CYP2C9,
             CYP2C19, CYP2D6 or the drug transporters Pgp (MDR1), BCRP, OATP1B1, OATP1B3, OCT1 and
             OCT2 and have a low therapeutic index that cannot be discontinued at least 7 days or 5
             x reported elimination half-life prior to start of treatment with any of the
             investigational drugs and for the duration of the study (Refer to Appendix 9).

         13. Known hypersensitivity to any study drug or component of the formulation.

         14. Pregnant or nursing (lactating) females.

         15. Vaccinated with live, attenuated vaccines within 4 weeks of the first dose of study
             drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Birgit Geoerger, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Birgit Geoerger, MD</last_name>
    <phone>1 42 11 4661</phone>
    <phone_ext>+33</phone_ext>
    <email>birgit.geoerger@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xavier Paoletti, MD</last_name>
    <phone>1 42 11 6564</phone>
    <phone_ext>+33</phone_ext>
    <email>xavier.paoletti@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Birgit Geoerger, MD</last_name>
      <phone>1 42 11 4661</phone>
      <phone_ext>+33</phone_ext>
      <email>birgit.geoerger@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Xavier Paoletti, MD</last_name>
      <phone>1 42 11 6564</phone>
      <phone_ext>+33</phone_ext>
      <email>xavier.paoletti@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Birgit Geoerger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Children's Hospitalermany</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olaf Witt, MD</last_name>
      <phone>6221 56 4555</phone>
      <phone_ext>+49</phone_ext>
      <email>O.Witt@Dkfz-Heidelberg.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michela Casanova, MD</last_name>
      <phone>02 23 90 25 94</phone>
      <phone_ext>+39</phone_ext>
      <email>Michela.Casanova@istitutotumori.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC, Sophia Children's Hospital</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Zwaan, MD</last_name>
      <phone>10 703 6691</phone>
      <phone_ext>+31</phone_ext>
      <email>c.m.zwaan@erasmusmc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unidad de Oncología Pediátrica Hospital Niño Jesús</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Bautista, MD</last_name>
      <phone>915 035 900</phone>
      <phone_ext>+43</phone_ext>
      <email>franciscojose.bautista@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pediatric and Adolescent Oncology The Royal Marsden Hospital</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynley Marshall, MD</last_name>
      <phone>208 661 3678</phone>
      <phone_ext>+44</phone_ext>
      <email>Lynley.Marshall@icr.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 21, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Olaparib</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Topotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

